TriSalus Life Sciences (TLSI) Equity Ratio (2022 - 2025)
Historic Equity Ratio for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to 0.73.
- TriSalus Life Sciences' Equity Ratio rose 144.44% to 0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73, marking a year-over-year increase of 144.44%. This contributed to the annual value of 1.08 for FY2024, which is 182.41% up from last year.
- As of Q3 2025, TriSalus Life Sciences' Equity Ratio stood at 0.73, which was up 144.44% from 0.47 recorded in Q2 2025.
- In the past 5 years, TriSalus Life Sciences' Equity Ratio ranged from a high of 0.25 in Q3 2023 and a low of 16.21 during Q2 2023
- In the last 4 years, TriSalus Life Sciences' Equity Ratio had a median value of 0.74 in 2024 and averaged 2.74.
- Over the last 5 years, TriSalus Life Sciences' Equity Ratio had its largest YoY gain of 64522.8% in 2023, and its largest YoY loss of 3508606.31% in 2023.
- Over the past 4 years, TriSalus Life Sciences' Equity Ratio (Quarter) stood at 8.02 in 2022, then skyrocketed by 86.28% to 1.1 in 2023, then increased by 1.82% to 1.08 in 2024, then skyrocketed by 32.15% to 0.73 in 2025.
- Its Equity Ratio was 0.73 in Q3 2025, compared to 0.47 in Q2 2025 and 1.2 in Q1 2025.